
Opinion|Videos|February 27, 2026
Fred Saad, MD, highlights phase 1 study of 225Ac-PSMA-Trillium in mCRPC
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Fact checked by: Hannah Clarke
Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.
Advertisement
In this video, Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study, assessing the investigational alpha-emitting radioligand therapy 225Ac-PSMA-Trillium (BAY 3563254) in patients with metastatic castration-resistant prostate cancer (mCRPC). These results were presented at the
Saad is a professor and chief of urology at University of Montreal Hospital Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













